APA (7th ed.) Citation

X, Z., Y, L., J, S., Y, C., J, G., H, R., . . . D, Z. (2026). Efficacy and safety of Shenqi Yangxin formula in patients with stable coronary artery disease based on CCTA: Rationale, design, and study protocol for a randomized, double-blind, placebo-controlled study. Frontiers in cardiovascular medicine, 13, 1697750. https://doi.org/10.3389/fcvm.2026.1697750

Chicago Style (17th ed.) Citation

X, Zhang, Liu Y, Sun J, Chen Y, Guo J, Ren H, Liu P, Wang C, and Zhang D. "Efficacy and Safety of Shenqi Yangxin Formula in Patients with Stable Coronary Artery Disease Based on CCTA: Rationale, Design, and Study Protocol for a Randomized, Double-blind, Placebo-controlled Study." Frontiers in Cardiovascular Medicine 13 (2026): 1697750. https://doi.org/10.3389/fcvm.2026.1697750.

MLA (9th ed.) Citation

X, Zhang, et al. "Efficacy and Safety of Shenqi Yangxin Formula in Patients with Stable Coronary Artery Disease Based on CCTA: Rationale, Design, and Study Protocol for a Randomized, Double-blind, Placebo-controlled Study." Frontiers in Cardiovascular Medicine, vol. 13, 2026, p. 1697750, https://doi.org/10.3389/fcvm.2026.1697750.